Recently, it has been shown that molecules inhibiting Bcl-2, but not Mcl-1, show promising anti-MM activity only in MM cell lines and patients with t(11;14) translocation, the same group that expresses high levels of both Bcl-2 and Bcl-Xl [13, 14]. Here, MCL1 is linked to Miyoshi myopathy.